Drugs targeting CCR5 in asymptomatic and CAD risk-
Post# of 147673
Quote:
Drugs targeting CCR5 in asymptomatic and CAD risk-factor/s-exposed individuals might be a novel therapeutic regime to diminish atherogenesis.
They were using the very first CCR5 blockade drug called DAPTA. It's not very effective so just think of what leronlimab can do in comparison.